The DCGI has directed state and UT drug controllers to monitor levels of the potentially carcinogenic NDMA in Ranitidine, an antacid. This action follows concerns about NDMA impurity and recommendations from the Drugs Technical Advisory Board (DTAB). Manufacturers are urged to take risk-based measures, including shelf-life reduction, while ICMR considers a safety study.